Nkarta Past Earnings Performance
Past criteria checks 0/6
Nkarta's earnings have been declining at an average annual rate of -17%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been declining at an average rate of 113.4% per year.
Key information
-17.0%
Earnings growth rate
59.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -113.4% |
| Return on equity | -25.7% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Nkarta, Inc.: Trying To Find Space In A Crowded Place
Jan 02Nkarta: Catalysts Ahead, But Competition In Cell Therapy Too (Rating Downgrade)
Oct 31We're Hopeful That Nkarta (NASDAQ:NKTX) Will Use Its Cash Wisely
Sep 10
Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients
Aug 14Nkarta: A Look Into Q1 Results And Upcoming Catalysts
May 23Nkarta: Down 50% Since March With A Clinical Catalyst Ahead
Apr 27Nkarta: NK Cell Therapy Advancement On Two Fronts
Mar 25Nkarta: Possible Upside From H1 Update, If Positive
Jan 25Here's Why We're Watching Nkarta's (NASDAQ:NKTX) Cash Burn Situation
Jan 16We're Keeping An Eye On Nkarta's (NASDAQ:NKTX) Cash Burn Rate
Oct 04We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth
Jun 21We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth
Mar 06Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation
Nov 20Nkarta GAAP EPS of -$0.61
Aug 11We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate
Jun 09Nkarta: A Promising Natural Killer Cell Play
May 20We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth
Aug 23Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans
May 10Nkarta gets greenlight from the FDA for NKX019 cancer study
Apr 28We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate
Jan 25
Revenue & Expenses Breakdown
How Nkarta makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -111 | 30 | 97 |
| 30 Jun 24 | 0 | -108 | 29 | 94 |
| 31 Mar 24 | 0 | -116 | 29 | 96 |
| 31 Dec 23 | 0 | -118 | 30 | 97 |
| 30 Sep 23 | 0 | -122 | 31 | 100 |
| 30 Jun 23 | 0 | -125 | 31 | 102 |
| 31 Mar 23 | 0 | -119 | 30 | 97 |
| 31 Dec 22 | 0 | -114 | 28 | 91 |
| 30 Sep 22 | 0 | -104 | 26 | 81 |
| 30 Jun 22 | 0 | -98 | 24 | 75 |
| 31 Mar 22 | 0 | -93 | 24 | 69 |
| 31 Dec 21 | 0 | -86 | 23 | 63 |
| 30 Sep 21 | 0 | -81 | 24 | 57 |
| 30 Jun 21 | 0 | -72 | 22 | 66 |
| 31 Mar 21 | 0 | -102 | 19 | 42 |
| 31 Dec 20 | 0 | -91 | 15 | 36 |
| 30 Sep 20 | 0 | -84 | 11 | 25 |
| 30 Jun 20 | 0 | -73 | 8 | 0 |
| 31 Mar 20 | 0 | -27 | 6 | 7 |
| 31 Dec 19 | 0 | -21 | 5 | 0 |
| 31 Dec 18 | 7 | 0 | 3 | 0 |
Quality Earnings: NKTX is currently unprofitable.
Growing Profit Margin: NKTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NKTX is unprofitable, and losses have increased over the past 5 years at a rate of 17% per year.
Accelerating Growth: Unable to compare NKTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NKTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (23.5%).
Return on Equity
High ROE: NKTX has a negative Return on Equity (-25.67%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 23:12 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nkarta, Inc. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Maughan | Canaccord Genuity |
| Alethia Young | Cantor Fitzgerald & Co. |
| Joshua Schimmer | Evercore ISI |